Clinical Trial

Pharmaco-proteomic Platform to Evaluate Drug Interactions in Liver Transplant Patients

Unknown
View on ClinicalTrials.gov →
Record status
This record was last updated November 12, 2024 (before its estimated December 5, 2024 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to enhance the ability to forecast kidney failure in liver transplant patients in the ICU under multidrug treatment by developing a computer platform that integrates mathematical models of drug interactions, proteomics, and clinical data. The main outcomes it aims to develop are: 1. Design the multidrug web computing platform with available information on drug pair interactions (DDIs). 2. Integrate the proteomic and clinical data of liver transplant patients into the IT platform. 3. Implement the multidrug web platform to predict the clinical evolution of liver transplant patients.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT06682325
Lead Sponsor Pontificia Universidad Catolica de Chile
Collaborators: Universidad de Valparaiso, Universidad Adolfo Ibañez
Conditions Drug-drug Interaction, Liver Transplantation
Enrollment 48 participants
Start Date 2023-06-01
Primary Completion 2024-12-05 (estimated)
Study Completion 2025-05-05 (estimated)
Updated on ClinicalTrials.gov 2024-11-12